- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05681286
CRP to Serum Albumin Ratio in Type 2 DM é Diabetic Nephropathy
C-reactive Protein to Serum Albumin Ratio in Type 2diabetic Patients With Diabetic Nephropathy
Study Overview
Status
Conditions
Detailed Description
Diabetic Nephropathy (DN) is a serious complication of Diabetes Mellitus associated with chronic and low-grade inflammatory burden affects around 30 % of diabetic patients (1) It is the leading cause of end-stage renal failure worldwide and associated with cardio vascular diseases and increases mortality of diabetic patients (2) It characterized by persistent albuminuria, raise in arterial blood pressure ,decrease in glomerular filtration rate (GFR))3) It associated with chronic low grade inflammation that's leads to increase glucose and activities inflammation (4)Despite of the pathogenesis of DN is multifactorial, but local inflammatory process may result from both the metabolic and hemodynamic affection seen in DN sustained diabetes-related metabolic and haemodynamic perturbations can induce subclinical low-grade renal inflammation and drive kidney from repair response to damage process, eventually to renal fibrosis (5,6) Chronic inflammatory processes not only play a principle role in the progression of micro vascular but also macro vascular complications in type 2 diabetes mellitus(7). An association between low -grade inflammation and type 2 diabetes has been described in recent studies .C- reactive protein to serum albumin ratio has attracted great attention recently , and used as biomarker in detection disease severity (1)
, since type 2 Diabetes Mellitus and Diabetic Nephropathy(DN) is associated with low grade inflammation in recent studies. In this study we presume that C-reactive protein to serum albumin ratio ( CAR )levels could be associated with the progression of DN in patients with T2DM.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Shymaa Shahhat, Master
- Phone Number: 01024302315
- Email: shoshahhat@yahoo.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria type 2diabetic patients
Exclusion Criteria:
- Type 1 diabetes is , pt with liver cirrhosis, patient with active infection ,pregnant women,
Patients with cancer
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Cross-Sectional
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
C-reactive protein to serum albumin ratio in type 2diabetic patients with diabetic nephropathy
Time Frame: Baseline
|
comparison between CAR level è type 2 diabetic nephropathy patient and those without nephropathy
|
Baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Salah Argoon, Assuit u
- Study Chair: Alshaimaa sayed, Assiut University
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAR level in type 2 DM
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 DM é Diabetic Nephropathy
-
Beni-Suef UniversityUnknownDiabetic Nephropathy Type 2 | Microalbuminuria Due to Type 2 Diabetes MellitusEgypt
-
Cairo UniversityCompletedVitamin k2 in Type 2 DMEgypt
-
Akebia TherapeuticsCyclerion TherapeuticsCompletedType 2 Diabetes Mellitus With Diabetic NephropathyUnited States
-
Zheng GuoNot yet recruitingDiabetic Nephropathy Type 2
-
The Third Xiangya Hospital of Central South UniversityCompletedType 2 Diabetic NephropathyChina
-
Centro Universitario de Ciencias de la Salud, MexicoUnknownDiabetic Nephropathy Type 2Mexico
-
Assiut UniversityUnknownDiabetic Nephropathy Type 2
-
Leiden University Medical CenterRadboud University Medical Center; Health Holland; Dutch Kidney FoundationCompletedGlucose Metabolism Disorders | Kidney Diseases | Diabetes Mellitus | Diabetic Nephropathies | Albuminuria | Microalbuminuria | Type2 Diabetes Mellitus | Diabetic Nephropathy Type 2 | Diabetic Complications Renal | South AsianNetherlands
-
Chinese PLA General HospitalBeijing Friendship Hospital; Xuanwu Hospital, Beijing; Beijing Tongren Hospital; Beijing Municipal Science & Technology Commission and other collaboratorsRecruitingDiabetic Kidney Disease | Type 2 Diabetes | Diabetic Nephropathy Type 2China
-
Second Affiliated Hospital, School of Medicine,...Second Affiliated Hospital of Wenzhou Medical University; Lishui Country People...RecruitingDiabetic Nephropathy Type 2 | BiomarkerChina